Items where authors include "Yea, C."

Conference abstract

Smith, M., Iverson, M., Hansen, E. et al. (2 more authors) (2023) A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers. [Conference abstract]

Bernstein, J., Riedl, M., Lumry, W. et al. (3 more authors) (2023) Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial. [Conference abstract]

Longhurst, H.J., Smith, M.D., Yea, C. et al. (1 more author) (2022) SEBETRALSTAT EFFECTIVENESS IN THE TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS RATED MILD OR MODERATE AT BASELINE IN THE PHASE 2 TRIAL. [Conference abstract]

Duckworth, E., Feener, E., Yea, C. et al. (3 more authors) (2022) Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated With Early Symptom Relief in Patients With Hereditary Angioedema. [Conference abstract]

Bernstein, J., Li, H., Yea, C. et al. (5 more authors) (2021) A022 on-demand oral treatment with kvd900 for hae attacks achieves rapid exposure and improves patient outcomes. [Conference abstract]

Yea, C., Audhya, P., Williams, P. et al. (1 more author) (2021) P052 relationship between PGI-C scale and other pros in KVD900 trial in HAE. [Conference abstract]